Innoviva Inc. diskutieren
Innoviva Inc.
WKN: A2AC9U / Symbol: INVA / Name: Innoviva / Aktie / Pharmazeutika / Small Cap /
?
-1,09 %
Innoviva, Inc. (NASDAQ: INVA) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $22.50 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) had its price target lowered by analysts at Morgan Stanley from $13.00 to $10.00. They now have an "underweight" rating on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $22.50 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for INVA provided by MarketBeat
Innoviva, Inc. (NASDAQ: INVA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $26.00 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) had its price target raised by analysts at Cantor Fitzgerald from $29.00 to $31.00. They now have an "overweight" rating on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) had its price target raised by analysts at HC Wainwright from $45.00 to $46.00. They now have a "buy" rating on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $35.00 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its price target raised by BTIG Research from $35.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its price target lowered by Cantor Fitzgerald from $36.00 to $34.00. They now have an "overweight" rating on the stock.
Ratings data for INVA provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in EyePoint Pharmaceuticals Inc. diskutieren